The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
May. 09, 2017

Filed:

Oct. 28, 2015
Applicants:

Abbvie S.á.r.l., Luxembourg, LU;

Galapagos NV, Mechelen, BE;

Inventors:

Robert J. Altenbach, Chicago, IL (US);

Andrew Bogdan, Evanston, IL (US);

Stephen N. Greszler, Vernon Hills, IL (US);

John R. Koenig, Chicago, IL (US);

Philip R. Kym, Libertyville, IL (US);

Bo Liu, Waukegan, IL (US);

Xenia B. Searle, Grayslake, IL (US);

Eric Voight, Pleasant Prairie, WI (US);

Xueqing Wang, Northbrook, IL (US);

Ming C. Yeung, Grayslake, IL (US);

Assignees:

AbbVie S.á.r.l., Luxembourg, LU;

Galapagos NV, Mechelen, BE;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07D 407/12 (2006.01); A61K 31/353 (2006.01); A61K 45/06 (2006.01); C07D 405/14 (2006.01); A61K 31/4433 (2006.01); C07D 491/052 (2006.01); A61K 31/436 (2006.01); A61K 31/4025 (2006.01); A61K 31/453 (2006.01); C07D 413/14 (2006.01); A61K 31/5377 (2006.01); A61K 31/397 (2006.01); C07D 491/107 (2006.01); A61K 31/435 (2006.01); A61K 31/00 (2006.01);
U.S. Cl.
CPC ...
A61K 31/353 (2013.01); A61K 31/00 (2013.01); A61K 31/397 (2013.01); A61K 31/4025 (2013.01); A61K 31/435 (2013.01); A61K 31/436 (2013.01); A61K 31/4433 (2013.01); A61K 31/453 (2013.01); A61K 31/5377 (2013.01); A61K 45/06 (2013.01); C07D 405/14 (2013.01); C07D 407/12 (2013.01); C07D 413/14 (2013.01); C07D 491/052 (2013.01); C07D 491/107 (2013.01);
Abstract

The invention provides for compounds of formula (I) wherein R, X, Y, R, R, R, R, R, R, R, R, R, R, R, m, and R″ have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions mediated and modulated by CFTR, including cystic fibrosis, Sjögren's syndrome, pancreatic insufficiency, chronic obstructive lung disease, and chronic obstructive airway disease. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).


Find Patent Forward Citations

Loading…